Anti-constipation composition
View Patent ↗An object of the present invention is to provide an anti-constipation composition containing a halogenated-bi-cyclic compound as an active ingredient in a ratio of bi-cyclic/mono-cyclic structure of at least 1:1. The halogenated-bi-cyclic compound is represented by Formula (I): where X 1 and X 2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache.
1. A method for relieving constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1.
2. The method according to claim 1 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is at least 20:1.
3. The method according to claim 1 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4.
4. A method for relieving constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1,and at least one medium fatty acid triglyceride, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1.
5. The method according to claim 4 , wherein said medium chain fatty acid triglyceride is a triglyceride of fatty acid having 6-14 carbon atoms.
6. The method according to claim 4 , wherein the triglyceride is present in an amount of 1-1,000,000 parts by weight based on one part by weight of the bi-cyclic structure.
7. The method according to claim 4 , wherein the triglyceride is present in an amount of 5-500,000 parts by weight based on one part by weight of the bi-cyclic structure.
8. The method according to claim 4 , wherein the triglyceride is present in an amount of 10-200,000 parts by weight based on one part by weight of the bi-cyclic structure.
9. The method according to claim 4 , wherein said triglyceride is caprylic acid triglyceride and/or capric acid triglyceride.
10. The method according to claim 4 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is at least 20:1.
11. The method according to claim 4 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4.
12. The method according to claim 1 , wherein the composition is free of water.
13. The method according to claim 4 , wherein the composition is free of water.
14. A method for treating constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1.
15. The method according to claim 14 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is at least 20:1.
16. The method according to claim 14 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4.
17. The method according to claim 14 , wherein the tautomers are present in the absence of water in the composition.
18. A method for treating constipation in a constipated patient or cleansing the bowel of a patient, comprising administering to said patient a therapeutically effective amount of a composition comprising the bi-cyclic and mono-cyclic tautomers of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E1, and at least one medium fatty acid triglyceride, wherein the ratio of the bi-cyclic to mono-cyclic tautomer is at least 1:1.
19. The method according to claim 18 , wherein said medium chain fatty acid triglyceride is a triglyceride of a fatty acid having 6-14 carbon atoms.
20. The method according to claim 18 , wherein the triglyceride is present in an amount of 1-1,000,000 parts by weight based on one part by weight of the bi-cyclic structure.
21. The method according to claim 18 , wherein the triglyceride is present in an amount of 5-500,000 parts by weight based on one part by weight of the bi-cyclic structure.
22. The method according to claim 18 , wherein the triglyceride is present in an amount of 10-200,000 parts by weight based on one part by weight of the bi-cyclic structure.
23. The method according to claim 18 , wherein said triglyceride is caprylic acid triglyceride and/or capric acid triglyceride.
24. The method according to claim 18 , wherein the ration of bi-cyclic to mono-cyclic tautomer is at least 20:1.
25. The method according to claim 18 , wherein the ratio of bi-cyclic to mono-cyclic tautomer is about 96:4.
26. The method according to claim 18 , wherein the tautomers are present in the absence of water in the composition.